Does Moderna Need to Start Making Money?
(NASDAQ: MRNA) is best known for its COVID-19 vaccines, which were fast-tracked for approval in 2020 and subsequently generated tens of billions of dollars in revenue.
However, a lot has changed in the past few years. Although Moderna's COVID-19 vaccines remain its primary revenue stream, sales are just a fraction of what they were during the pandemic. Plus, the company is losing money hand over fist, posting a $2.8 billion net loss in 2025 and expecting billions in losses in 2026 as well.
Based on this, you might think Moderna would be a terrible investment. But I'm not sure that's the case, and there are three main reasons why.
Source Fool.com
Moderna Inc. Stock
€59.24
0.250%
Based on 9 Buy predictions and 9 Sell predictions the sentiment towards Moderna Inc. is rather balanced.
A target price of 21 € results in a potential of -64.55% which would mean heavy losses compared to the current price of 59.24 € for Moderna Inc..
